STO · BRAIN.ST
BrainCool AB (publ)
SEK 1.03-SEK 0.04 (-3.37%)
BrainCool AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 10.26% below the high.
Loading market information…
STO · ACUC.ST · SEK
Stock price
Quote as of Oct 21, 2026, 02:40 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
AcuCort AB’s quoted price sits in the lower half of its reported 52-week range, 58.11% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Specializing in pharmaceutical innovation, AcuCort AB (publ) focuses on the development and commercialization of glucocorticoid dexamethasone film products, particularly for acute allergic conditions. Among its offerings is Zeqmelit, a medication with diverse therapeutic uses. Zeqmelit addresses severe and acute allergic reactions, pediatric croup, chemotherapy-induced nausea and vomiting, and also serves as a treatment for COVID-19 patients who require supplemental oxygen. The company, established in 2006, is headquartered in Lund, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:28 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 1.03-SEK 0.04 (-3.37%)
BrainCool AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 10.26% below the high.
SEK 13.00-SEK 2.85 (-17.98%)
Xbrane Biopharma AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.0% below the high.
SEK 12.65-SEK 0.40 (-3.07%)
SciBase Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 76.57% below the high.
SEK 0.52+SEK 0.01 (+1.37%)
Klaria Pharma Holding AB (publ.)’s quoted price sits in the lower half of its reported 52-week range, 60.98% below the high.
SEK 0.38+SEK 0.00 (+1.08%)
Alzinova AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 81.86% below the high.
SEK 14.70-SEK 0.30 (-2.0%)
Q-linea AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 61.74% below the high.
SEK 0.55+SEK 0.01 (+1.85%)
Neola Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.5% below the high.
SEK 0.81-SEK 0.08 (-8.58%)
Enorama Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 71.68% below the high.
